PERCUTANEOUS ABLATIONS Clinical Criteria: Exclusion Contraindications: - Pulmonary hypertension - Malignant Effusion Abbas G, et al. Surg Oncol 2009;100(8):645-50 Relative contraindications: - Poor lung function: FEV11L respiratory failure...

Rational for ablation Its effective (technically, oncologically, economically, ...) Its minimally-invasive Its easy to perform and safe Its still constantly evolving (new generators, smaller applicators, computer-based treatment planning,...

Invited Submission: CIRSE Standards of Practice Guidelines Published: 21 January 2012 Standards of Practice: Guidelines for Thermal Ablation of Primary and Secondary Lung Tumors...

Lung Cancer Therapeutic options Surgical resection Pneumonectomy, lobectomy, wedge resection, VATS, ... Ablation RFA, MWA, Cryo, ... RTH: SBRT, 3DCRT, ... Systemic CHT, immunotherapy, 分子靶向 ......

Minna JD. Harrisons principals of internal medicine. New York: McGraw-Hill 2005;506-516. Primary NSCLC (88%) SCLC microcytoma (advanced at diagnoses) Metastases Colon cancer Breast cancer Osteosarcoma Melanoma Neck cancers...

从60,70年代发展起来的这一技术，差不多算是一项古老的技术，曾经被证明对生存率没有影响的技术，几十年过去了，如今它 - Is it logical? - Is it dangerous? - Is it effective? Are there any study is to clarify these interrogative points（疑问点） an...

REFLCT研究全球患者数据：与索拉非尼相比，乐卫玛(甲磺酸仑伐替尼)显著改善PFS和TTP，且OS不劣于索拉非尼 REFLCT研究中国患者数据：与索拉非尼相比，乐卫玛(甲磺酸仑伐替尼)显著改善OS、PFS和TTP...

如上图所示，Lenvatinib主要通过四条途径发挥作用： 1、通过抑制受体型蛋白酪氨酸激酶FGFR1-4）解除对抗血管生成药物的耐药性； 2、通过抑制血管内皮生长因子受体（VEGFR1-3）抑制肿瘤新生毛细血管生成； 3、通过抑制原癌基因（RET, KIT）和血小板衍生生长因...

Curr Opin Gastroenterol 2020 Feb 25[Online ahead of print] New Systemic Agents for Hepatocellular Carcinoma: An Update 2020 Johann von Felden 1 Affiliations expand PMID: 32101985 DOI: 10.1097/MOG.0000000000000626 Abstract Purpose of review...

甲状腺癌（SELECT研究，24mg，每日一次）蛋白尿发生比例34%，3级蛋白尿发生比例为11%。 肾癌（Study205，18mg仑伐替尼+5mg依维莫司，每日一次）蛋白尿发生比例31%，3级蛋白尿发生比例为8%。 肝癌（REFLECT研究，8mg 或 12mg，每日一次）蛋白尿发生比例26%，3...